|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 912 East Capitol Street NE |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105617-51
|
||||||||
|
6. House ID# 447300005
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Elizabeth Karan |
Date | 10/18/2024 5:26:04 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Appropriations for the National Breast and Cervical Cancer Early Detection Program
Appropriations for breast cancer research
Appropriations for cancer prevention and control
Policies related to access to supplemental and diagnostic breast imaging
FY25 House and Senate Labor-HHS Appropriations bills (H.R. 9029/S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025)
Policies related to report language on the implementation of the Medicare Prescription Payment Plan.
Policies related to the transparent use of artificial intelligence, via patient notification, and validation of its use, scaling and outcomes in breast cancer screening.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464)
Safe Step Act (H.R.2630/S. 652)
Implementation of the Affordable Care Act
HELP Copays Act (H.R.830/S.1375)
Cancer survivorship issues
Issues related to prescription drug affordability for patients
Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging
Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging
Find It Early Act (H.R.3086/S.5141); a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals
Policies related to coverage of preventive services with no cost-sharing
Polices regarding White House Cancer Moonshot implementation
Policies related to copay accumulator and maximizer adjustors
H.J. Res. 181, Congressional Review Act resolution to stop the Biden-Harris rule limiting access to Association Health Plans (AHPs)
Policies related to the extension of enhanced advanced premium tax credits
Healthcare Affordability Act of 2024 (H.R. 9774 / S. 5194)
H.R. 1692 - Health Care Affordability Act of 2023; a bill to revise the tax credit for health care premium assistance to expand the eligibility of low-income taxpayers for such credit and reduce the cost of health care premiums
S. 8 - Improving Health Insurance Affordability Act of 2023; a bill to expand the eligibility of taxpayers for the refundable tax credit for coverage under a qualified health plan and increases cost-sharing subsidies under the Patient Protection and Affordable Care Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Office of Personnel Management (OPM), Office of Science & Technology Policy (OSTP), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, White House Office, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Metastatic Breast Cancer Access to Care Act (S. 663 / HR 549)
Medicare coverage policy for breast cancer treatments and services
Telehealth
Policies related to funding, state incentives, and federal efforts for Medicaid expansion
Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid
Policies related to Medicare coverage for pharmacy services
Medicare coverage policy for drugs and drug pricing
H.R.3086/S.5141 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals
Medicaid unwinding, the process for redetermination of Medicaid eligibility
Medicare Drug Pricing Negotiation implementation
Preserving and expanding access to Medicaid
Policy related to medical billing for breast reconstruction surgery called DIEP flap, a type of natural tissue breast reconstruction that uses non-breast tissue to replace breast tissue
Community Health Worker Access Act which is a bill to amend titles XVIII and XIX of the Social Security Act to increase access to community health workers under the Medicare and Medicaid programs (S. 3892)
Policy related to medical billing for breast reconstruction surgery called DIEP flap, a type of natural tissue breast reconstruction that uses non-breast tissue to replace breast tissue
Comments in response to CY 2025 Medicare Physician Fee Schedule
Comments in response to CY 2025 Medicare HOPPS proposed rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health disparities
Access to clinical trials for underrepresented populations
Policies related to cancer survivorship
Policies related to medications access in during emergencies
Polices related to PBM and drug cost transparency
Policies related to reducing the cost of cancer treatment for patients
Policies related to decline in breast cancer screenings during the COVID-19 pandemic
Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840)
Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act
Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis
Policies related to the regulation of diagnostic devices, including comments on the proposed rule to regulate Medical Devices; Laboratory Developed Tests
The Patent Eligibility Restoration Act (S.2140)
Policies related to ICD-10 code for inflammatory breast cancer
Comments in response to Congressional Next-Generation Cures package
Comments in response to the House Energy & Commerce Committee Framework for Discussion on Reforming the National Institutes of HealthProhibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V) (CFPB-2024- 0023)
Comments in response to Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies (FDA-2021D-0789)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Centers For Disease Control & Prevention (CDC), Consumer Financial Protection Bureau (CFPB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Outreach to the Dr. Bertagnolli, NIH Director, and the Office of the Director
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Karan |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |